Blair William & Co. IL Sells 16,942 Shares of Sarepta Therapeutics, Inc. $SRPT

Blair William & Co. IL reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 38.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,173 shares of the biotechnology company's stock after selling 16,942 shares during the period. Blair William & Co. IL's holdings in Sarepta Therapeutics were worth $465,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Inspire Investing LLC bought a new position in Sarepta Therapeutics during the 1st quarter valued at about $967,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Sarepta Therapeutics by 54.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 463,342 shares of the biotechnology company's stock valued at $29,570,000 after acquiring an additional 164,041 shares in the last quarter. Tempus Wealth Planning LLC increased its position in Sarepta Therapeutics by 475.8% in the 2nd quarter. Tempus Wealth Planning LLC now owns 20,658 shares of the biotechnology company's stock valued at $353,000 after acquiring an additional 17,070 shares in the last quarter. Assenagon Asset Management S.A. increased its position in Sarepta Therapeutics by 21.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 867,939 shares of the biotechnology company's stock valued at $14,842,000 after acquiring an additional 155,358 shares in the last quarter. Finally, Trexquant Investment LP acquired a new stake in Sarepta Therapeutics in the 1st quarter valued at about $11,997,000. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $22.51 on Friday. The firm's 50 day moving average price is $19.61 and its two-hundred day moving average price is $29.44. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. The firm has a market cap of $2.20 billion, a P/E ratio of -25.87 and a beta of 0.51. Sarepta Therapeutics, Inc. has a twelve month low of $10.41 and a twelve month high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $1.13. The business had revenue of $611.09 million for the quarter, compared to analyst estimates of $530.66 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The firm's revenue for the quarter was up 68.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.07 earnings per share. On average, analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SRPT has been the subject of several research reports. Leerink Partners raised their price objective on shares of Sarepta Therapeutics from $12.00 to $15.00 and gave the company a "market perform" rating in a research report on Tuesday, September 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Sarepta Therapeutics in a research report on Tuesday. Mizuho restated a "neutral" rating and issued a $14.00 price objective (down previously from $40.00) on shares of Sarepta Therapeutics in a research report on Monday, July 21st. Guggenheim restated a "buy" rating and issued a $22.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, September 15th. Finally, HC Wainwright reiterated a "sell" rating on shares of Sarepta Therapeutics in a research report on Monday, August 25th. Eight equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and seven have given a Sell rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of "Hold" and an average target price of $34.42.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.